Product Description
Mechanisms of Action: TLR9 Agonist
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mologen AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: HIV Infections
Phase 1: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2016-00276 | P1 |
Active, not recruiting |
Melanoma |
2025-05-31 |
|
| TITAN | P2 |
Active, not recruiting |
HIV Infections |
2020-10-25 |